Loading…
IMRN
Immuron Ltd
NASDAQ· Healthcare· Biotechnology· CUSIP 45254U101
$1.15-1.29%Price as of Aug 29, 18:42 UTC · updated once a day, after the close
Key metrics
- Market cap
- $9.28M
- P/E
- —
- Forward P/E
- —
- P/B
- 1.0x
- Dividend yield
- —
- Payout
- —
- EPS
- -$0.53
- ROE
- -39.68%
- Profit margin
- -62.14%
- Revenue growth
- +4.80%
- Beta
- 0.51
- 52-week high
- $2.39
- 52-week low
- $0.68
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -68.4% over 5Y.
today you would have $292.19▼ -70.8%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 4 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Year-end price | $0.76 | $1.70 | $1.88 | $2.08 | |
| P/S | 157.9x | 24.5x | 79.1x | 236.7x | 619.2x |
| P/B | 21.9x | 22.1x | 30.5x | 21.8x | 20.4x |
| EPS | -$0.91 | -$1.22 | -$0.66 | — | |
| Profit margin | -175.65% | -71.58% |
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| XBIOXenetic Biosciences, Inc. | $3.98 | — | 1.2x | — | -47.04% | $9.33M |
| TRAWTraws Pharma, Inc. | $0.59 | — | 5.3x | — | -433.36% | $9.07M |
| APUSApimeds Pharmaceuticals US, Inc. | $6.30 | — | 9.7x | — | — | $9.51M |
| MBAIMBody AI Ltd. | $6.58 |
About the company
Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, the United States, and Canada. It operates through two segments, Research and Development; and Hyper-immune Products. The company offers Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and risk of minor gastrointestinal disorders, as well as a dietary supplement for digestive tract protection; and Protectyn, an immune supplement to help maintain a healthy digestive function and liver. It also develops Travelan (IMM-124E), which is in Phase II clinical trial, to reduce the risk of contracting travelers' diarrhea; and IMM-529, which is in Phase II clinical trial, for treating patients suffering from recurring clostridium difficile infection. In additon, the company develops IMM-986, that is in pre-clinical stage. Further, it offers technology platform. The company has a collaboration with the US Naval Medical Research Command and Silver Spring, MD, USA to develop and clinically evaluate a therapeutic targeting Campylobacter and enterotoxigenic Escherichia coli infections; and a research collaboration with the Walter Reed Army Institute of Research to develop three Shigella-specific therapeutic products. The company was formerly known as Anadis Limited and changed its name to Immuron Limited in December 2008. Immuron Limited was incorporated in 1994 and is headquartered in Carlton, Australia.
- 7
- Carlton, Australia
Company description provided by Yahoo Finance.